Skip to main content
SpringerLink
Log in

Relapse and Rehospitalisation Rates in Patients with Schizophrenia

Effects of Second Generation Antipsychotics

  • Review Article
  • Published:
CNS Drugs Aims and scope Submit manuscript

Abstract

Recent studies suggest that the risk of relapse in patients with schizophrenia is approximately 3.5% per month. Predictors of more frequent relapses include poor compliance with antipsychotic drug treatment, severe residual psychopathology, poor insight into the illness and the need for treatment, comorbid substance abuse, and poor relationships between patients, families and care providers. Although conventional antipsychotic drugs, such as haloperidol and fluphenazine, are effective in preventing relapse, second generation antipsychotic drugs, such as clozapine, risperidone and olanzapine, appear to be superior in preventing relapse and improving the patient’s quality of life. The development of adverse events can undermine treatment response and relapse prevention. Minimising adverse effects thus helps to improve treatment compliance and prevent relapse. Second generation antipsychotic drugs tend to have fewer adverse effects than conventional agents, especially pseudoparkinsonism and akathisia. The societal costs of treating patients with schizophrenia can be lessened by employing strategies that decrease relapse and the need for rehospitalisation, the most costly treatment alternative.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III
Table IV

Similar content being viewed by others

References

  1. Andreasen NC, Arndt S, Alliger R, et al. Symptoms of schizophrenia: methods, meanings and mechanisms. Arch Gen Psychiatry 1995; 52: 341–51

    Article  PubMed  CAS  Google Scholar 

  2. Green MF. What are the consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry 1996; 153: 321–30

    PubMed  CAS  Google Scholar 

  3. Tollefson GD, Sanger TM, Lu Y, et al. Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol. Arch Gen Psychiatry 1998; 55: 250–8

    Article  PubMed  CAS  Google Scholar 

  4. Weiden PJ, Olfson M. Cost of relapse in schizophrenia. Schizophr Bull 1995; 21: 419–29

    Article  PubMed  CAS  Google Scholar 

  5. Doering S, Muller E, Kopcke W, et al. Predictors of relapse and rehospitalisation in schizophrenia and schizoaffective disorder. Schizophr Bull 1998; 24: 87–98

    Article  PubMed  CAS  Google Scholar 

  6. Haywood TW, Kravitz HM, Grossman LS, et al. Predicting the ‘revolving door’ phenomenon among patients with schizophrenic, schizoaffective, and affective disorders. Am J Psychiatry 1995; 152: 856–61

    PubMed  CAS  Google Scholar 

  7. Kent S, Yellowlees P. Psychiatric and social reasons for frequent hospitalization. Hosp Community Psychiatry 1994; 45: 347–50

    PubMed  CAS  Google Scholar 

  8. Sullivan G, Wells KB, Morgenstern H, et al. Identifying modifiable risk factors for rehospitalisation: a case-control study of seriously mentally ill persons in Mississippi. Am J Psychiatry 1995; 152: 1749–56

    PubMed  CAS  Google Scholar 

  9. Olfson M, Mechanic D, Hansell S, et al. Predicting medication noncompliance after hospital discharge among patients with schizophrenia. Psychiatr Serv 2000; 51: 216–22

    Article  PubMed  CAS  Google Scholar 

  10. Olfson M, Mechanic D, Boyer CA, et al. Assessing clinical predictions of early rehospitalisation in schizophrenia. J Nerv Ment Dis 1999; 187:721–9

    Article  PubMed  CAS  Google Scholar 

  11. Angermeyer MC, Goldstein JM, Kuehn L. Gender differences in schizophrenia: rehospitalisation and community survival. Psychol Med 1989; 19: 365–82

    Article  PubMed  CAS  Google Scholar 

  12. Haro JM, Eaton WW, Bilker WB, et al. Predictability of rehospitalisation for schizophrenia. Eur Arch Psychiatry Clin Neurosci 1994; 244: 241–6

    Article  PubMed  CAS  Google Scholar 

  13. Postrado LT, Lehman AF. Quality of life and clinical predictors of rehospitalisation of persons with severe mental illness. Psychiatr Serv 1995; 46: 1161–5

    PubMed  CAS  Google Scholar 

  14. Caton CLM, Showlong PK, Fleiss JL, et al. Rehospitalisation in chronic schizophrenia. J Nerv Ment Dis 1985; 173: 139–48

    Article  PubMed  CAS  Google Scholar 

  15. Laessle R, Pfister H, Wittchen H-U. Risk of rehospitalisation of psychotic patients: a 6-year follow-up investigation using the survival approach. Psychopathology 1987; 20: 48–60

    Article  PubMed  CAS  Google Scholar 

  16. Davis JM. Maintenance therapy and the natural course of schizophrenia. J Clin Psychiatry 1985; 11: 18–21

    Google Scholar 

  17. Kane JM, Lieberman JA. Maintenance pharmacotherapy in schizophrenia. In: Meltzer HY, editor. Psychopharmacology, the third generation of progress: the emergence of molecular biology and biological psychiatry. New York: Raven Press, 1987: 1103–9

    Google Scholar 

  18. Schooler NR, Keith SJ, Severe JB, et al. Relapse and rehospitalisation during maintenance treatment of schizophrenia: the effects of dose reduction and family treatment. Arch Gen Psychiatry 1997; 54: 453–63

    Article  PubMed  CAS  Google Scholar 

  19. Schooler NR. Maintenance medication for schizophrenia: strategies for dose reduction. Schizophr Bull 1991; 17: 311–24

    Article  PubMed  CAS  Google Scholar 

  20. Hogarty GE, McEvoy JP, Munetz M, et al. Dose of fluphenazine, familial expressed emotion, and outcome in schizophrenia. Arch Gen Psychiatry 1988; 45: 797–805

    Article  PubMed  CAS  Google Scholar 

  21. Kane JM, Rifkin A, Woerner M, et al. Low-dose neuroleptic treatment of outpatient schizophrenics. I: preliminary results for relapse rates. Arch Gen Psychiatry 1983; 40: 893–6

    CAS  Google Scholar 

  22. Marder SR, Van Putten T, Mintz J, et al. Low- and conventional-dose maintenance therapy with fluphenazine decanoate: two-year outcome. Arch Gen Psychiatry 1987; 44: 518–21

    Article  PubMed  CAS  Google Scholar 

  23. Kane JM, Davis JM, Schooler NR, et al. A one-year comparison of four dosages of haloperidol decanoate. Schizophr Res 1993; 9: 239–40

    Article  Google Scholar 

  24. Farde L, Nordstrom A-L, Wiesel F-A, et al. Positron emission tomographic analysis of central dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine: relation to extrapyramidal side effects. Arch Gen Psychiatry 1992; 49: 538–44

    Article  PubMed  CAS  Google Scholar 

  25. Van Putten T, Crumpton E, Yale C. Drug refusal in schizophrenia and the wish to be crazy. Arch Gen Psychiatry 1976; 33: 1443–6

    Article  PubMed  Google Scholar 

  26. Van Putten T. Why do schizophrenic patients refuse to take their drugs? Arch Gen Psychiatry 1974; 31: 67–72

    Article  PubMed  Google Scholar 

  27. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994; 151: 825–35

    PubMed  CAS  Google Scholar 

  28. Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizo-phrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45: 789–96

    Article  PubMed  CAS  Google Scholar 

  29. Breier A, Buchanan RW, Kirkpatrick B, et al. Clozapine in schizophrenic outpatients: efficacy, long-term outcome, and relationship to prefrontal cortex. Schizophr Res 1993; 9: 257–8

    Article  Google Scholar 

  30. Lindstrom E, Eriksson B, Hellgren A, et al. Efficacy and safety of risperidone in the long-term treatment of patients with schizophrenia. Clin Ther 1995; 17: 402–12

    Article  PubMed  CAS  Google Scholar 

  31. Csernansky JG, Mahmoud R, Brenner R. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med 2002; 346: 16–22

    Article  PubMed  CAS  Google Scholar 

  32. Dellva MA, Tran P, Tollefson GD, et al. Standard olanzapine versus placebo and ineffective-dose olanzapine in the maintenance treatment of schizophrenia. Psychiatr Serv 1997; 48(12): 1571–7

    PubMed  CAS  Google Scholar 

  33. Hamilton SH, Edgell ET, Revicki DA, et al. Functional outcomes in schizophrenia: a comparison of olanzapine and haloperidol in a European sample. Int Clin Psychopharmacol 2000; 15: 245–55

    Article  PubMed  CAS  Google Scholar 

  34. Meltzer HY, Burnett S, Bastani B, et al. Effects of six months of clozapine treatment on the quality of life of chronic schizophrenic patients. Hosp Community Psychiatry 1990; 41: 892–7

    PubMed  CAS  Google Scholar 

  35. Purdon, SE. Measuring neuropsychological change in schizophrenia with novel antipsychotic medications. J Psychiatry Neurosci 2000; 25: 108–16

    PubMed  CAS  Google Scholar 

  36. Di Lorenzo R, Tondelli G, Genedani S. Effectiveness of clozapine and olanzapine: a comparison in severe, psychotically ill patients. Int J Neuropsychopharmacol 2001; 4: 135–7

    PubMed  Google Scholar 

  37. Chouinard G, Jones B, Remington G, et al. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993; 13: 25–40

    Article  PubMed  CAS  Google Scholar 

  38. Claus A, Bollen J, De Cuyper H, et al. Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multi-center double-blind comparative study. Acta Psychiatr Scand 1992; 85: 295–305

    Article  PubMed  CAS  Google Scholar 

  39. Tran PV, Hamilton SH, Kuntz AJ, et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 1997; 17: 407–18

    Article  PubMed  CAS  Google Scholar 

  40. Copolov DL, Link CG, Kowalcyk B. A multicentre, double-blind, randomized comparison of quetiapine (ICI 204,636, ‘Seroquel’) and haloperidol in schizophrenia. Psychol Med 2000; 30: 95–105

    Article  PubMed  CAS  Google Scholar 

  41. Keck PE, Reeves KR, Harringan EP, et al. Ziprasidone in the short-term treatment of patients with schizoaffective disorder: Results from two double-blind, placebo-controlled, multicenter studies. J Clin Psychopharmocol 2001; 21: 27–35

    Article  CAS  Google Scholar 

  42. Stimmel GL, Gutierrez MA, Lee V. Ziprasidone: an atypical antipsychotic drug for the treatment of schizophrenia. Clin Ther 2002; 24: 21–37

    Article  PubMed  CAS  Google Scholar 

  43. Arvanitis L, Miller BG. Multiple fixed doses of ‘Seroquel’ (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo: the Seroquel Trial 13 Study Group. Biol Psychiatry 1997; 42: 233–46

    Article  PubMed  CAS  Google Scholar 

  44. Daniel DG, Copeland LF. Ziprasidone: comprehensive overview and clinical use of a novel antipsychotic. Expert Opin Investig Drugs 2000; 9: 819–28

    Article  PubMed  CAS  Google Scholar 

  45. Perkins DO. Adherence to antipsychotic medications. J Clin Psychiatry 1999; 60Suppl. 21: 25–30

    PubMed  Google Scholar 

  46. Stanniland C, Taylor D. Tolerability of atypical antipsychotics. Drug Saf 2000; 22: 195–214

    Article  PubMed  CAS  Google Scholar 

  47. Adler LA, Angrist B, Reiter S, et al. Neuroleptic-induced akathisia: a review. Psychopharmacology 1989; 97: 1–11

    Article  PubMed  CAS  Google Scholar 

  48. Braude WM, Barnes TRE, Gore SM. Clinical characteristics of akathisia. Br J Psychiatry 1983; 143: 134–50

    Article  Google Scholar 

  49. Levinson DF, Simpson GM, Singh H, et al. Fluphenazine dose, clinical response, and extrapyramidal symptoms during acute treatment. Arch Gen Psychiatry 1990; 47: 761–8

    Article  PubMed  CAS  Google Scholar 

  50. Newcomer JW, Miller LS, Faustman WO, et al. Correlations between akathisia and residual psychopathology: a by-product of neuroleptic-induced dysphoria. Br J Psychiatry 1994; 164: 834–8

    Article  PubMed  CAS  Google Scholar 

  51. Van Putten T, Marder SR, Mintz J. A controlled dose comparison of haloperidol in newly admitted schizophrenic patients. Arch Gen Psychiatry 1990; 47: 754–8

    Article  PubMed  Google Scholar 

  52. Singh MM. Dysphoric response to neuroleptic treatment in schizophrenia and its prognostic significance. Dis Nerv Syst 1976; 37: 191–6

    PubMed  CAS  Google Scholar 

  53. Van Putten T, May PRA. Subjective response as a predictor of outcome in pharmacotherapy. Arch Gen Psychiatry 1978; 35: 477–80

    Article  PubMed  Google Scholar 

  54. American Psychiatric Association. Practice guidelines for the treatment of patients with schizophrenia. Am J Psychiatry 1997 Apr; 154(4): 1–63

    Google Scholar 

  55. Beasley CM, Dellva MA, Tamura RN, et al. Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol. Br J Psychiatry 1999; 174: 23–30

    Article  PubMed  CAS  Google Scholar 

  56. Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999; 156: 1686–96

    PubMed  CAS  Google Scholar 

  57. Henderson DC. Clozapine: diabetes mellitus, weight gain, and lipid abnormalities. J Clin Psychiatry 2001; 62Suppl. 23: 39–44

    PubMed  CAS  Google Scholar 

  58. Wirshing DA, Spellberg BJ, Erhart SM, et al. Novel antipsychotics and new onset diabetes. Biol Psychiatry 1998; 44: 778–83

    Article  PubMed  CAS  Google Scholar 

  59. Wirshing DA, Pierre JM, Eyeler J, et al. Risperidone-associated new-onset diabetes. Biol Psychiatry 2001; 50: 148–9

    Article  PubMed  CAS  Google Scholar 

  60. Buis W. Patients’ opinions concerning side effects of depot neuroleptics. Am J Psychiatry 1992; 149: 844–5

    PubMed  CAS  Google Scholar 

  61. Sussman N. Review of atypical antipsychotics and weight gain. J Clin Psychiatry 2001; 62 Suppl. 23: 5–12

    Google Scholar 

  62. Geddes J, Freemantle N, Harrison P, et al. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 2000; 321: 1371–6

    Article  PubMed  CAS  Google Scholar 

  63. Drake RE, Erhlich J. Suicide attempts associated with akathisia. Am J Psychiatry 1985; 142: 499–501

    PubMed  CAS  Google Scholar 

  64. Keckica WA. Violence as a manifestation of akathisia [letter]. JAMA 1978; 240: 2185

    Article  Google Scholar 

  65. Kalinowsky LB. Appraisal of the ‘tranquilizers’ and their influence on other somatic treatments in psychiatry. Am J Psychiatry 1958; 115: 294–300

    PubMed  CAS  Google Scholar 

  66. Knapp M. Schizophrenia costs and treatment cost-effectiveness. Acta Psychiatr Scand 2000; 102Suppl. 407: 15–8

    Article  Google Scholar 

  67. Horvitz-Lennon M, Normand ST, Gaccione P, et al. Partial versus full hospitalization for adults in psychiatric distress: a systematic review of the published literature (1957–1997). Am J Psychiatry 2001; 158: 676–85

    Article  PubMed  CAS  Google Scholar 

  68. Honigfeld G, Patin J. A two-year clinical and economic follow-up of patients on clozapine. Hosp Community Psychiatry 1990; 41: 882–5

    PubMed  CAS  Google Scholar 

  69. Rabinowitz J, Lichtenberg P, Kaplan Z, et al. Rehospitalisation rates of chronically ill schizophrenic patients discharged on a regimen of risperidone, olanzapine, or conventional antipsychotics. Am J Psychiatry 2001; 158: 266–9

    Article  PubMed  CAS  Google Scholar 

  70. Conley RR, Love RC, Kelly DL, et al. Rehospitalisation rates of patients recently discharged on a regimen of risperidone or clozapine. Am J Psychiatry 1999; 156: 863–8

    PubMed  CAS  Google Scholar 

  71. Rosenheck R, Cramer J, Weichun X, et al. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. N Engl J Med 1997; 337: 809–15

    Article  PubMed  CAS  Google Scholar 

  72. Jonsson D, Walinder J. Cost-effectiveness of clozapine treatment in therapy-refractory schizophrenia. Acta Psychiatr Scand 1995; 92: 199–201

    Article  PubMed  CAS  Google Scholar 

  73. Revicki DA. Pharmacoeconomic studies of atypical antipsychotic drugs for the treatment of schizophrenia. Schizophr Res 1999; 35: S101–9

    Article  PubMed  Google Scholar 

  74. Moore DB, Kelly DL, Sherr JD, et al. Rehospitalisation rates for depot antipsychotics and pharmacoeconomic implications: comparison with risperidone. Am J Health Syst Pharm 1998; 55(4 Suppl.): S17–9

    PubMed  CAS  Google Scholar 

Download references

Acknowledgements

Public Health Service Grants MH56584 and MH62130 provided support for the preparation of this article. Dr Csernansky has received grant support and honorariums from Janssen Pharmaceuticals, Eli Lilly and Co. and AstraZeneca Pharmaceuticals.

Author information

Authors and Affiliations

  1. Department of Psychiatry (Box 8134), Washington University School of Medicine, and Metropolitan St. Louis Psychiatric Center, 660 S. Euclid Ave., St. Louis, Missouri, 63110, USA

    John G. Csernansky & Emily K. Schuchart

Authors
  1. John G. Csernansky
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Emily K. Schuchart
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to John G. Csernansky.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Csernansky, J.G., Schuchart, E.K. Relapse and Rehospitalisation Rates in Patients with Schizophrenia. Mol Diag Ther 16, 473–484 (2002). https://doi.org/10.2165/00023210-200216070-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00023210-200216070-00004

Keywords

Search

Navigation